Your browser doesn't support javascript.
loading
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.
Schoenmaker, Linde; Witzigmann, Dominik; Kulkarni, Jayesh A; Verbeke, Rein; Kersten, Gideon; Jiskoot, Wim; Crommelin, Daan J A.
Afiliação
  • Schoenmaker L; Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, 2300 RA Leiden, the Netherlands.
  • Witzigmann D; Department of Biochemistry and Molecular Biology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada; NanoMedicines Innovation Network (NMIN), University of British Columbia, Vancouver, BC, Canada.
  • Kulkarni JA; Department of Biochemistry and Molecular Biology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada; NanoMedicines Innovation Network (NMIN), University of British Columbia, Vancouver, BC, Canada.
  • Verbeke R; Ghent Research Group on Nanomedicines, Faculty of Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.
  • Kersten G; Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, 2300 RA Leiden, the Netherlands; Coriolis Pharma, Fraunhoferstrasse 18b, 82152 Martinsried, Germany.
  • Jiskoot W; Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, 2300 RA Leiden, the Netherlands; Coriolis Pharma, Fraunhoferstrasse 18b, 82152 Martinsried, Germany. Electronic address: w.jiskoot@lacdr.leidenuniv.nl.
  • Crommelin DJA; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, the Netherlands. Electronic address: d.j.a.crommelin@uu.nl.
Int J Pharm ; 601: 120586, 2021 May 15.
Article em En | MEDLINE | ID: mdl-33839230
ABSTRACT
A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they have to be stored at (ultra)low temperatures. Understanding the root cause of the instability of these vaccines may help to rationally improve mRNA-LNP product stability and thereby ease the temperature conditions for storage. In this review we discuss proposed structures of mRNA-LNPs, factors that impact mRNA-LNP stability and strategies to optimize mRNA-LNP product stability. Analysis of mRNA-LNP structures reveals that mRNA, the ionizable cationic lipid and water are present in the LNP core. The neutral helper lipids are mainly positioned in the outer, encapsulating, wall. mRNA hydrolysis is the determining factor for mRNA-LNP instability. It is currently unclear how water in the LNP core interacts with the mRNA and to what extent the degradation prone sites of mRNA are protected through a coat of ionizable cationic lipids. To improve the stability of mRNA-LNP vaccines, optimization of the mRNA nucleotide composition should be prioritized. Secondly, a better understanding of the milieu the mRNA is exposed to in the core of LNPs may help to rationalize adjustments to the LNP structure to preserve mRNA integrity. Moreover, drying techniques, such as lyophilization, are promising options still to be explored.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanopartículas / COVID-19 Limite: Humans Idioma: En Revista: Int J Pharm Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanopartículas / COVID-19 Limite: Humans Idioma: En Revista: Int J Pharm Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda